Purpose of Study. The goal of this clinical research study is to assess the safety of mature, autologous dendritic cells (DC) combined with recombinant human prostate specific membrane antigen (rPSMA) to treat patients with metastatic, hormone refractory prostate cancer. Another goal is to monitor the immune response.
Appears in 2 contracts
Sources: Clinical Trial Agreement (Northwest Biotherapeutics Inc), Clinical Trial Agreement (Northwest Biotherapeutics Inc)